Manufacturer of Controlled Substances; Notice of Application, 10679 [05-4227]
Download as PDF
<![CDATA[
10679
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
Schedule II.
The company plans to manufacture a
cocaine derivative to be used as an
intermediate for the production of
Dopascan Injection. Cocaine derivatives
are a Schedule II controlled substance in
the cocaine basic class.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Guilford Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Guilford Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
VerDate jul<14>2003
19:07 Mar 03, 2005
Jkt 205001
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4202 Filed 3–3–05; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
By Notice dated September 16, 2004,
and published in the Federal Register
on September 30, 2004, (69 FR 58542–
58533), Lifepoint, Inc., 10400
Trademark Street, Rancho Cucamonga,
California 91730, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedules I and II:
Drug
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on November
11, 2004, JFC Technologies, LLC, 100
West Main Street, Bound Brook, New
Jersey 08805, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of the basic class of
controlled substances listed in Schedule
II:
Matthey Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
BILLING CODE 4410–09–P
By Notice dated November 22, 2004
and published in the Federal Register
on December 6, 2004, (69 FR 70470),
Johnson Matthey, Inc., Pharmaceutical
Materials, 2003 Nolte Drive, West
Deptford, New Jersey 08066, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
class of controlled substances listed in
Schedule II.
BILLING CODE 4410–09–P
Diphenozylate (9170) ....................
Hydrocodone (9193) .....................
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4227 Filed 3–3–05; 8:45 am]
Importer of Controlled Substances;
Notice of Registration
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4198 Filed 3–3–05; 8:45 am]
Drug
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 3, 2005.
Schedule
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
II
II
II
The company plans to import the
listed controlled substances as raw
materials for use in the manufacture of
bulk controlled substances for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Johnson Matthey Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Johnson
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Drug
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Phencyclidine (7471) ....................
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
Schedule
I
II
II
II
II
II
The company plans to produce small
quantities of controlled substances for
use in drug test kits.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Lifepoint, Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Lifepoint, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Page 10679]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4227]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 11, 2004, JFC
Technologies, LLC, 100 West Main Street, Bound Brook, New Jersey 08805,
made application by renewal to the Drug Enforcement Administration
(DEA) for registration as a bulk manufacturer of the basic class of
controlled substances listed in Schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Diphenozylate (9170)........................ II
Hydrocodone (9193).......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
Virginia 22301; and must be filed no later than May 3, 2005.
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-4227 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P
